Focused On-demand Library for Interleukin-6 receptor subunit beta

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

CDw130; Interleukin-6 signal transducer; Membrane glycoprotein 130; Oncostatin-M receptor subunit alpha

Alternative UPACC:

P40189; A0N0L4; Q5FC04; Q9UQ41


Interleukin-6 receptor subunit beta, also known as CDw130, plays a pivotal role in signal transduction for a variety of cytokines, including IL6, LIF, and OSM. It facilitates the formation of a high-affinity receptor complex, activating JAK-MAPK and JAK-STAT3 signaling pathways. This activation is crucial for immune response, hematopoiesis, and bone metabolism. The protein is also essential for embryonic development and the survival of motor and sensory neurons.

Therapeutic significance:

Interleukin-6 receptor subunit beta is implicated in several immunologic disorders, such as Hyper-IgE recurrent infection syndrome and Stuve-Wiedemann syndrome. Its involvement in these diseases, characterized by recurrent infections, skeletal abnormalities, and immunodeficiency, underscores its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.